Rogers’ miss is not the story; the curamik reset is the investable fulcrum

The print should be read as a reset quarter, not a clean recovery quarter, because the numbers argue both sides and the market is likely over-indexing on the wrong one. What was priced in was a modest sequential revenue recovery and a return to positive adjusted earnings, with Street revenue at $205.7 million and EPS at $0.50. What actually surprised was that revenue came in light at $202.8 million, a -1.4% surprise, while EPS missed by -32.0% at $0.34. That combination usually says operational leverage failed to show up. Here, the variant perception is more specific: the revenue miss was small enough to keep the end-market stabilization thesis alive, while the EPS miss forces investors to underwrite whether the curamik restructuring can convert a 31.6% gross margin base into the guided step-up next quarter. The stock debate should move from “did Q2 beat?” to “is $13 million of cost savings credible against a revenue base still stuck near $200 million?”

That distinction matters because the company’s own call framing was careful, not promotional. Ali El-Haj said, “Sales increased by 6.5% from the prior quarter, led by a stronger industrial, portable electronics, A&D and ADAS end markets.” The wording is useful because it names multiple end markets rather than one hero product, which reduces the risk that the sequential pickup was a single customer timing event. It also does not claim a broad-cycle turn, and the year-over-year revenue line supports that restraint: Q2 revenue was still down -5.3%. A manager should therefore not pay for a demand inflection yet. The investable case is that a modest top-line recovery, even one that only moves revenue back toward the low end of the recent range, can matter if the cost base is finally being cut where gross margin lives.

The financial trajectory shows why the market can miss that nuance. Revenue has been pinned near the low $200 million area after falling from the higher 2023 base, while gross margin has not reclaimed the mid-30s level that was visible before the downturn. Q2’s 31.6% gross margin was better than Q1’s 29.9%, but still below Q2 FY2024’s 34.1%, so the sequential improvement is not enough by itself. EPS also tells a messy story because GAAP was hit by curamik charges, while adjusted earnings are the cleaner operating basis for the Street comparison. Laura Russell made the bridge explicit on the company’s basis: “Adjusted earnings per share in Q2 increased to $0.34 from the $0.27 in Q1 as a result of the improvement in sales and gross margin.” That sentence matters because management is tying earnings power to the same two inputs investors can monitor next quarter, not to below-the-line noise.

The capacity and cost story explains why the Q3 guide is more important than the Q2 miss. Management guided Q3 revenue to $200 million to $215 million, and the midpoint implies only “a 2% increase in sales versus the previous quarter,” per Russell. That is not a demand-surge guide. The margin guide carries the more actionable signal: gross margin of 31.5% to 33.5%, with “a 90-basis point improvement at the midpoint of our range.” If the company can reach that margin range on only a low-single-digit sequential revenue lift, the market will have to separate margin self-help from cyclical revenue recovery. If it cannot, the quarter’s EPS miss was not just a one-quarter disappointment, it was evidence that the cost base remains too heavy for the current demand environment.

The reason curamik sits at the center of the thesis is that the charge was large enough to obscure the quarter but the savings target is large enough to affect the model. On a GAAP basis, Rogers recorded a net loss of $73.6 million, or $4 per share, including $4.3 million of restructuring costs and a $71.8 million noncash impairment charge tied to goodwill and other intangible assets for curamik. The impairment itself is not cash earnings power, but it is an admission that the asset’s prior carrying value no longer fits the outlook. More important, management expects total restructuring costs for curamik European operations of $12 million to $20 million from Q3 of ’25 to Q3 of ’26, against annual run-rate savings projected to be greater than $13 million. The economics are not trivial for a company producing Q2 adjusted EBITDA of $23.9 million, because the targeted savings are mainly cost of sales and therefore should show up first in gross margin if execution is real.

The balance sheet adds a capital-allocation wrinkle that is easy to misread. Cash ended Q2 at $157 million, down $18.4 million from the end of Q1, and the company spent $28.1 million on share repurchases. Repurchasing stock into a quarter with a -32.0% EPS surprise can look tone-deaf if one treats the miss as the thesis. It looks different if one believes management has identified a cost-savings program with measurable payback and a path to higher gross margin. The buyback does not prove value, but it does raise the bar for execution because the company also has restructuring cash costs ahead and capital expenditures of $8.1 million in Q2. With approximately $76 million remaining on the repurchase authorization, the correct investor question is not whether Rogers can buy stock, but whether it should continue doing so unless the Q3 gross-margin midpoint is delivered.

The call delivery supports a cautious version of that constructive read, because management sounded more confident than the prior quarter but not evasive enough to dismiss the uncertainty. The Q2 FY2025 transcript scored 0.33 on sentiment and 0.70 on tone_confidence, while uncertainty was 32.0. Compared with Q1 FY2025, where tone_confidence was 0.30 and uncertainty was 71.5, the delivery improved materially. The caveat is that Q&A sentiment was only 0.16, below prepared_sentiment of 0.39, which says management’s scripted narrative was cleaner than the analyst exchange. That gap fits the investment debate: the prepared remarks can lay out the restructuring and guidance math, but investors still need evidence that the savings land while revenue is only guided to inch higher. The tone history therefore confirms a management team that was more numerically anchored, not one that removed the debate.

That tone matters because the company’s most ambitious operating comments were about responsiveness, not just cost. El-Haj said Rogers is trying to take lead times in some product lines and plants “down by 50% to 60%.” The quote earns attention because lead-time reduction is a second-order demand enabler, not merely a factory metric: shorter lead times can help win orders in industrial, portable electronics, A&D and ADAS when customers are reluctant to commit far ahead. But investors should not capitalize that benefit yet, because the same call guided only a 2% sequential revenue increase at the Q3 midpoint. In other words, management is pointing to process improvements that could improve conversion, while its formal guide still assumes a muted demand environment. That is a healthy tension, not a contradiction.

The read-through for the supply chain is deliberately narrow because the data pack names no specific customers or suppliers for Rogers. That absence itself constrains portfolio action: this print should not be used to make a customer-specific or supplier-specific call where none is identified. The only defensible second-order read-through is by end market. Industrial, portable electronics, A&D and ADAS were all named as contributors to the 6.5% sequential sales increase, while AES revenue rose 4.6% and EMS revenue rose 8.2% quarter on quarter. That implies the improvement was not isolated to one segment, and it gives competitors in substrates and engineered materials a modest demand signal. The magnitude is modest because the company’s own Q3 midpoint is only 2% above the prior quarter, so the read-through is stabilization, not a demand acceleration.

The peer comparison sharpens the point that Rogers’ problem is not gross-margin ceiling in the subsector, but revenue momentum and asset quality. In the latest peer table, Rogers shows 32.2% gross margin and +5.2% revenue YoY, while AXTI shows 29.6% gross margin and +39.1% revenue YoY. Rogers’ margin is higher, but AXTI’s growth is far stronger, so Rogers is not the clean growth vehicle in the group. Against Japanese substrates peers, 3445.T reports 32.3% gross margin and +8.7% revenue YoY, which frames Rogers as near the upper end on margin but still lagging on growth. That comparison matters for PMs because the long Rogers case cannot rest on relative top-line momentum. It has to rest on the view that cost actions can restore earnings power before the cycle offers much help.

The cleanest way to underwrite that view is to separate accounting loss from operating repair. The GAAP loss was dominated by the $71.8 million noncash impairment, and that makes the reported diluted EPS line unusable as a standalone gauge of run-rate earnings. The Street-comparison EPS miss still matters, because adjusted EPS of $0.34 was below the $0.50 estimate, but the impairment does not tell us whether Q3 gross margin can move toward the guided range. The operating evidence is narrower: sales rose sequentially, gross margin rose to 31.6%, and adjusted EBITDA reached $23.9 million. Those figures do not justify a victory lap. They justify watching whether a leaner curamik footprint can lift margin without needing a revenue breakout.

The risk to the thesis is that the restructuring savings become a bridge to nowhere if demand remains trapped around $200 million. Revenue was $202.8 million in Q2, and Q3 guidance starts at $200 million, so the downside of the range effectively allows no sequential growth. The EPS guide also leaves room for disappointment, with GAAP EPS projected from breakeven to $0.40 and adjusted EPS from $0.50 to $0.90. That spread reflects the remaining restructuring and adjustment complexity, and it means investors need to insist on gross margin rather than EPS alone as the confirmation metric. A quarter with adjusted EPS in range but gross margin below 31.5% would be lower quality; a quarter with gross margin near 33.5% on revenue within the guide would validate the self-help thesis.

What to watch next is therefore precise. For Q3 FY2025, revenue must land inside the $200 million to $215 million guide, but the real confirmation is gross margin within 31.5% to 33.5% and evidence that the midpoint improvement of 90 basis points is not deferred. The break point is a margin print below 31.5%, because that would undercut the claim that curamik actions and cost-of-sales savings are already changing the earnings base. The second checkpoint is adjusted EPS versus the $0.50 to $0.90 range, with any shortfall requiring an explanation that does not rely on revenue if sales are near the guided midpoint. Finally, track restructuring costs against the $12 million to $20 million program through Q3 of ’26 and annual run-rate savings greater than $13 million; by the next call, investors need evidence that the impairment quarter was the start of margin repair, not just the quarter Rogers wrote down the past.